Micafungin
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Neutropenia
Conditions
Neutropenia, Hematopoietic Stem Cell Transplantation, Invasive Fungal Disease
Trial Timeline
Apr 1, 2010 → May 1, 2012
NCT ID
NCT01135589About Micafungin
Micafungin is a approved stage product being developed by Astellas Pharma for Neutropenia. The current trial status is unknown. This product is registered under clinical trial identifier NCT01135589. Target conditions include Neutropenia, Hematopoietic Stem Cell Transplantation, Invasive Fungal Disease.
What happened to similar drugs?
7 of 17 similar drugs in Neutropenia were approved
Approved (7) Terminated (5) Active (8)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03174457 | Pre-clinical | Completed |
| NCT03102658 | Approved | Completed |
| NCT02440178 | Phase 2 | Completed |
| NCT03421002 | Phase 2 | Completed |
| NCT02678598 | Pre-clinical | Completed |
| NCT02127788 | Pre-clinical | Completed |
| NCT02646800 | Approved | Terminated |
| NCT02646774 | Approved | Terminated |
| NCT02057289 | Phase 1 | Terminated |
| NCT01982071 | Approved | Terminated |
| NCT01135589 | Approved | UNKNOWN |
| NCT00606268 | Phase 1 | Completed |
| NCT00608335 | Phase 1 | Completed |
| NCT00818584 | Phase 1 | Completed |
| NCT00842504 | Phase 1 | Completed |
Competing Products
20 competing products in Neutropenia